• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Tolebrutinib is Not Superior to Teriflunomide in the Treatment of Relapsing Multiple Sclerosis

byAstrid BradshawandAlisha Yi
April 21, 2025
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click here to read this study in NEJM. 

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Axonal injury may occur up to 9 years prior to symptom onset in multiple sclerosis

Serum neurofilament light chain elevations may be viable as a biomarker for multiple sclerorsis

#VisualAbstract: Inhibition of CD40L with Frexalimab in Multiple Sclerosis Reduces the Number of New Gadolinium-Enhancing T1 Weighted Lesion

Tags: multiple sclerosisrelapsing multiple sclerosisteriflunomidetolebrutinib
Previous Post

2 Minute Medicine Rewind April 21, 2025

Next Post

#VisualAbstract: Reduced-Dose Apixaban was Noninferior to Full-Dose for Cancer-Associated Venous Thromboembolism

RelatedReports

Chronic Disease

Axonal injury may occur up to 9 years prior to symptom onset in multiple sclerosis

May 19, 2025
Chronic Disease

Serum neurofilament light chain elevations may be viable as a biomarker for multiple sclerorsis

May 23, 2024
#VisualAbstract: Inhibition of CD40L with Frexalimab in Multiple Sclerosis Reduces the Number of New Gadolinium-Enhancing T1 Weighted Lesion
StudyGraphics

#VisualAbstract: Inhibition of CD40L with Frexalimab in Multiple Sclerosis Reduces the Number of New Gadolinium-Enhancing T1 Weighted Lesion

March 8, 2024
Chronic Disease

Frexalimab CD40L inhibition slows the progression of multiple sclerosis

March 6, 2024
Next Post
#VisualAbstract: Dapagliflozin Reduced Death and Worsening Heart Failure in Transcatheter Aor-tic-Valve Implantation

#VisualAbstract: Reduced-Dose Apixaban was Noninferior to Full-Dose for Cancer-Associated Venous Thromboembolism

Ultrasound-guided radiofrequency ablation may be effective for treatment of aldosterone-producing adenomas

#VisualAbstract: Inebilizumab Improves Outcomes in Generalized Myasthenia Gravis

#VisualAbstract: Inebilizumab Improves Outcomes in Generalized Myasthenia Gravis

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Diabetic polyneuropathy observed to have dynamic changes overtime
  • Left atrial appendage closure is noninferior to oral anticoagulation after ablation for atrial fibrillation
  • Obinutuzumab plus standard therapy is efficacious in managing active lupus nephritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.